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fibrillation. Circulation 2005;111:1100–5.Letters to the EditorLate Gadolinium Enhancement
in Left Ventricular Dysfunction
After Trastuzumab
We read with great interest the report by Fallah-Rad et al. (1)
regarding echocardiography, biomarkers, and cardiac magnetic
resonance (CMR) in patients with trastuzumab-induced heart
failure. Cardiotoxicity after chemotherapy remains a clinical chal-
lenge. There is great interest in early detection of myocardial
damage before left ventricular (LV) function deteriorates, and
CMR is a good candidate to deliver this information. CMR isin various systemic and inflammatory diseases using specific
techniques (2). We would like to focus on the late gadolinium
enhancement (LGE) CMR findings.
The authors state in their discussion that “delayed enhancement
of the lateral wall of the LV within the mid-myocardium portion
[represents] a common feature in breast-cancer patients with
trastuzumab-induced cardiomyopathy.” This is an interesting find-
ing with a potentially high clinical impact. However, from our
point of view, more evidence is required to support this general
statement. Their current paper is the third publication by the
group regarding this subject with the same single CMR image
(once as a magnitude image, twice as a phase-sensitive reconstruc-
tion) depicting an intramural lateral lesion (1,3,4). This LGEeast 1rienci
n Coe
1.61
1.02
1.38lesion in itself is unspecific and may or may not be related to
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image before chemotherapy for comparison. The paper describes
baseline CMR, including T2-weighted imaging, in the Methods
section, but does not report results. Our own experience with
CMR imaging after trastuzumab therapy instead points to revers-
ibly impaired LV function without LGE lesions, corresponding to
previous findings in echocardiography (5). So far, the authors are
the first to report LGE lesions after trastuzumab; therefore,
confirmatory studies by other groups are required. CMR might
have the potential to visualize tissue changes after chemotherapy
independent from changes in LV function and thereby guiding
patient management.
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Clinical Risk Stratification
of Chemotherapy-Induced
Cardiac Dysfunction
I read with great interest the recent publication by Fallah-Rad et
al. (1) on chemotherapy-induced cardiac dysfunction. I applaud
the authors for this integrated research in cardio-oncology utilizing
a multi-imaging modality, including cardiovascular magnetic res-
onance as I advocated in a previous publication (2).
Despite the valuable insights into early diagnosis of chemotherapy-
induced cardiac dysfunction provided by this study, there remain a
few unanswered clinical questions. First, among the cohort with
trastuzumab-associated cardiac dysfunction, what was the contri-bution from coronary artery disease (CAD) or ischemic heart
disease? CAD has been identified as a risk factor for chemotherapy
(3); additionally, antimetabolite chemotherapy agents, such as
5-fluorouracil, may be associated with ischemic heart disease (4).
Second, what was the impact of antiplatelet therapy on the results?
Aspirin therapy, part of the primary cardiovascular prevention
armamentarium, may also be beneficial in cancer patients, includ-
ing those with thrombocytopenia (5). Third, what was the statin
utilization rate among this cohort of cancer patients and its
impact on study outcome? In an animal model, statin pre-
treatment with fluvastatin attenuated doxorubicin-induced car-
diotoxicity (6).
This study demonstrates the promise of combined biomarker
and multi-imaging tools for early diagnosis of chemotherapy-
induced cardiac dysfunction; however, clinical cardiovascular risk
stratification of the cancer patients and survivors on chemotherapy
remains to be fully elucidated.
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Early Identification of
Left Ventricular Dysfunction
Induced by Trastuzumab
Cardiac monitoring and managing of patients receiving antineo-
plastic therapy is an actual issue. We agree with the interesting
article by Fallah-Rad et al. (1): new, sensitive indexes of cardiac
function are needed to predict cardiac dysfunction before ejection
fraction (EF) is compromised. Normal hearts have enormous
recruitable contractile capacity, and to show a decrease in EF, the
